Arcturus Bio Invited to 2025 Vaccine and Therapeutic RNA Research Forum Headlined by Nobel Laureate to Discuss the Future of RNA Innovation
Abogen
Nucleic Acid Drug Developer
Dr. Ying Bo, Founder, Chairman and CEO of Abogen Biosciences, attended as the only invited representative from China on August 4th to 5th in Bangkok, Thailand."2025 Vaccine and Therapeutic RNA Research Forum" (Vaccine and Therapeutic RNA Research Forum 2025)`, and delivered two important speeches on the first day to share the latest developments of Abogen in the field of mRNA vaccines and therapeutic RNA research.`
This forum was jointly organized by the Chulalongkorn University Vaccine Research Center (Chula VRC), the Global Health Institute of the Faculty of Medicine at Chulalongkorn University (CHULASGH), and the UK-Southeast Asia Vaccine Manufacturing Research Hub (UK-SEA Vax Hub).2023 Nobel Prize in Physiology or Medicine Laureate, Pioneer of mRNA Technology, and Professor at the University of Pennsylvania, Drew Weissman, Led the Lecture。
Forum Site
Dr. Drew Weissman
2023 Nobel Prize Winner
Professor at the University of Pennsylvania
The forum brings together top scientists from around the world in various fields such as mRNA vaccines, therapeutic RNA, Lipid Nanoparticle platforms, and pandemic prevention and control, dedicated to promoting global cooperation and development in RNA technology.。
Abogen Sharing Session
Dr. Abogen Delivers a Speech
Details of the Keynote Speech
Keynote Talk 01
Subject:AI-Driven mRNA and Cationic Lipid Development
Time:August 4, 2025 10:00–10:30
Summary:
① Introduced the establishment of Abogen's xRNA (mRNA, circRNA, saRNA) platform and demonstrated how to use AI technology to optimize platform development and automate production processes;
② Reported the progress of Abogen's current platform in clinical projects, including the preliminary clinical safety data of the Varicella Zoster Virus (VZV) and Respiratory Syncytial Virus (RSV) vaccine projects, as well as the latest clinical efficacy and safety data of the ABO2203 project (mRNA-encoded CD3/CD19 bispecific antibody);
③ Further prospects for the potential of Abogen's xRNA platform in more application scenarios
Details of the Keynote Speech
Keynote Talk 02
Subject:Comparison and Potential Applications of mRNA, circular RNA and self-amplifying RNA Platform
Time:August 4, 2025 10:50–11:05
Summary:Introduction and Comparison of Abogen's Proprietary xRNA Platform: Covering Three Technical Pathways—Linear RNA, Circular RNA, and Self-Amplifying RNA—Respectively Elaborating on Their Characteristics, Advantages, Challenges, and the Potential in Various Application Scenarios.
Dr. Abogen Visits Chulalongkorn University
Research and Innovation Center
Dr. Bo Ying with Dr. Drew Weissman
About the Conference
This forum focuses on cutting-edge topics such as mRNA vaccine delivery systems, therapeutic RNA, and pandemic prevention and control, covering hot directions like T-cell-targeting LNP therapy, the application of mRNA-LNP in autoimmune diseases, the development of small interfering RNA (siRNA), vaccine accessibility and equity for developing countries, and AI-assisted lipid design. It aims to promote global vaccine technology innovation and cooperation, advancing the benefits of RNA technology to broader populations.
Chula VRC, one of the organizers, was established in 2017 and serves as the core institution for vaccine research and development in Thailand. It is committed to creating an RNA vaccine platform accessible to middle- and low-income countries. Its research areas cover vaccines for infectious diseases such as dengue fever and leptospirosis, as well as allergic diseases, aiming to develop and provide safe, effective, and affordable vaccines for the benefit of Thailand and neighboring countries.。
